Subconjunctival injection of anti-VEGF agent bevacizumab as treatment in patients with dry eye disease.

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pakistan journal of pharmaceutical sciences Pub Date : 2024-09-01
Muhammad Kaunain Ghoghari, Zeeshan Kamil, Hunain Razzak, Syed Fawad Rizvi, Syed Ali Afsar, Muhammad Tanweer Hassan Khan
{"title":"Subconjunctival injection of anti-VEGF agent bevacizumab as treatment in patients with dry eye disease.","authors":"Muhammad Kaunain Ghoghari, Zeeshan Kamil, Hunain Razzak, Syed Fawad Rizvi, Syed Ali Afsar, Muhammad Tanweer Hassan Khan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>To assess the effect of subconjunctival injection of anti-VEGF bevacizumab in the management of dry eye disease in a tertiary care hospital. In this quasi-experimental trial 150 eyes of 75 patients were selected using non-probability consecutive sampling technique. Detailed clinical examination was performed, the ocular surface disease index (OSDI) questionnaire score, tear film break-up time (TBUT) and Schirmer test 2 were measured and compared pre and post injection. Six patients were excluded and sixty-six patients were included having the mean age was 65.3 (SD=±10.2) years, 50% were aged 66-83 years old, 65.2% were female. Pre injection OSDI score was 30.3 (SD=±2.79), whereas post injection it was 20.2 (SD=±3.01). Pre injection TBUT was 3.0 (SD=±0.30), whereas post injection it was 5.17 (SD=±0.40). Pre injection Schirmer 2 test was 7.97 (SD=±0.51), whereas post injection it was 10.5 (SD=±0.50). Ten patients suffered mild subconjunctival hemorrhage which resolved spontaneously. Three patients were lost to follow up. Subconjunctival injection of anti-VEGF agent bevacizumab can offer a modern and safe solution in patients suffering from dry eye disease nevertheless more trials with large number of patients and longer follow up durations are required for widespread adaptation.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

To assess the effect of subconjunctival injection of anti-VEGF bevacizumab in the management of dry eye disease in a tertiary care hospital. In this quasi-experimental trial 150 eyes of 75 patients were selected using non-probability consecutive sampling technique. Detailed clinical examination was performed, the ocular surface disease index (OSDI) questionnaire score, tear film break-up time (TBUT) and Schirmer test 2 were measured and compared pre and post injection. Six patients were excluded and sixty-six patients were included having the mean age was 65.3 (SD=±10.2) years, 50% were aged 66-83 years old, 65.2% were female. Pre injection OSDI score was 30.3 (SD=±2.79), whereas post injection it was 20.2 (SD=±3.01). Pre injection TBUT was 3.0 (SD=±0.30), whereas post injection it was 5.17 (SD=±0.40). Pre injection Schirmer 2 test was 7.97 (SD=±0.51), whereas post injection it was 10.5 (SD=±0.50). Ten patients suffered mild subconjunctival hemorrhage which resolved spontaneously. Three patients were lost to follow up. Subconjunctival injection of anti-VEGF agent bevacizumab can offer a modern and safe solution in patients suffering from dry eye disease nevertheless more trials with large number of patients and longer follow up durations are required for widespread adaptation.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结膜下注射抗血管内皮生长因子药物贝伐珠单抗治疗干眼症患者。
目的:评估在一家三级医院结膜下注射抗血管内皮生长因子贝伐单抗治疗干眼症的效果。在这项准实验性试验中,采用非概率连续抽样技术选取了 75 名患者的 150 只眼睛。对患者进行了详细的临床检查,测量了眼表疾病指数(OSDI)问卷评分、泪膜破裂时间(TBUT)和施尔默试验 2,并对注射前后进行了比较。排除了 6 名患者,纳入了 66 名患者,平均年龄为 65.3(SD=±10.2)岁,50% 的患者年龄在 66-83 岁之间,65.2% 为女性。注射前 OSDI 评分为 30.3(SD=±2.79),注射后为 20.2(SD=±3.01)。注射前 TBUT 为 3.0(SD=±0.30),注射后为 5.17(SD=±0.40)。注射前的 Schirmer 2 试验为 7.97(SD=±0.51),而注射后为 10.5(SD=±0.50)。10 名患者出现轻微结膜下出血,但已自行消退。3 名患者失去了随访机会。结膜下注射抗血管内皮生长因子药物贝伐珠单抗可为干眼症患者提供一种现代而安全的解决方案,但要广泛适应这种疗法,还需要进行更多的试验、更多的患者和更长的随访时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
211
审稿时长
4.5 months
期刊介绍: Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.
期刊最新文献
Ethanolic extracts of Sterculia guttata: Exploring the neuroprotective effects on memory and cognitive impairment in scopolamine-induced Alzheimer's disease rats. Natural sesquiterpene zingiberene exerts ameliorative effects on growth of glioblastoma cells by instigating ROS mediated apoptosis. New dynamic scoring method for deep evaluation of naloxegol as β-tubulin binding inhibitor. Sanhuang ointment prolongs indwelling time and promotes vein injury repair in patients receiving intravenous infusion via peripheral venous indwelling needles. Assessment of the impact of combining butylphthalide and atorvastatin on neurological function, quality of life and vascular endothelial function in individuals diagnosed with acute cerebral infarction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1